The Food and Drug Administration approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. The company's ...

Pfizer (NYSE:PFE) said the FDA has approved its vaccine Abrysvo for the vaccination of expectant mothers to help protect babies against RSV during the first months of life. The vaccine is ...

A Pfizer Inc. PFE, -0.48% vaccine designed to protect babies from respiratory syncytial virus, or RSV, got a green light Monday from the U.S. Food and Drug Administration — a key milestone for ...

The CDC specifically recommended that expectant mothers 32 to 36 weeks into their pregnancy receive the shot, Pfizer's ...

Here's a breakdown of every vaccine you'll need this season. The US Centers for Disease Control and Prevention last week ...

An advisory panel for the U.S. Centers of Disease Control and Prevention on Friday recommended that a vaccine for respiratory ...

The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. - Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.

The FDA approved the first vaccine for pregnant women to prevent RSV in infants. The vaccine would allow babies to be born ...

Washington — U.S. regulators on Monday approved the first RSV vaccine for pregnant women so their babies will be born with protection against the scary respiratory infection. RSV is notorious ...

The FDA has approved the first long acting drug to protect infants and toddlers from the respiratory virus known as RSV. The antibody preventive therapy called, was approved Monday for injection ...

This is a carousel. Use Next and Previous buttons to navigate WASHINGTON (AP) — U.S. regulators on Monday approved the first RSV vaccine for pregnant women so their babies will be born with ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...